Phase ISmall Molecule
Compound 61728
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061728
Risk Class
MODERATE
Last Audit
Jul 3, 2108
Research Abstract
Small Molecule candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61728 is a small molecule asset inside small molecule innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in phase i with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061728 with updates logged 2108-07-03.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61728Small Molecule Program 61728
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061728
- [2] Operations Pulse • Small Molecule innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61728